Page 12 - Revista Portuguesa - SPORL - Vol 61. Nº4

Figure 4
Measured psychophysical (olfactory perception thresholds [OPT]) and subjective (visual analog scale
[VAS]) olfaction scores at baseline, 1 month and 3 months after treatment, from general linear models
adjusted for baseline score.

by OPT. The same process was applied to VAS after . As pCIOD can significantly affect a
13
score with the ANOVA determining that VAS patient´s quality of life, there is a need for
differed significantly across the three time effective treatment solutions In this regard,
1.
points (F (2,16) = 12.923, p = 0.004). A post hoc PRP restores optimism by introducing a new
pairwise comparison using the Bonferroni potential treatment alternative.
correction showed an increased VAS score This study´s primary purpose was to determine
between baseline and 1-month follow-up PRP injection´s efficacy, safety and feasibility
assessments (4.1 vs 6.2, respectively), but this in treating pCIOD. The primary objective of
was not statistically significant (p = 0.075). this work was met. Both the psychophysical
Nevertheless, the VAS score increment reached (OPT) and subjective (VAS) olfaction scores
significance when comparing the baseline to exhibited significant improvement from the
the 3-months follow-up assessments (4.1 vs 8, baseline to the 1-month and 3-months post-
p = 0.008). Therefore, results from the ANOVA injection evaluations. These findings are in
indicate a significant effect of PRP injection line with recent Literature. In an innovative
on olfactory function across time as measured pilot study published in 2020, Yan et al. first
by VAS score. Regarding complications, only introduced the concept of applying PRP to
one case of vasovagal episode was noted manage long-lasting olfactory dysfunction .
9
during the procedure, with no incurring cases The results showed significant improvement
of epistaxis or septal perforation during the in olfactory function in all patients receiving
3-months´ follow-up. PRP treatment, but included a limited sample
of 7 patients . The same group published the
9
Discussion first randomized trial results of PRP application
COVID-19 pandemic reinforced the pertinency against placebo in pCIOD patients in late
of furtherly exploring the enigmatic world of 2022, with favorable outcomes, mainly noted
olfactory science. To date, it is unknown why on olfactory discrimination . Meanwhile, other
10
some COVID-19 patients experience pCIOD groups contributed significantly with larger
whereas others restore function shortly PRP injected cohorts. Heba A. Abo El Naga

350 Revista Portuguesa de Otorrinolaringologia - Cirurgia de Cabeça e Pescoço